Reduced intensity conditioning stem cell transplantation for lymphoid and myeloid malignancies in Australia and New Zealand

Fludarabine Melphalan Conditioning provides similar disease control in both Lymphoid and Myeloid Malignancies – A retrospective analysis of 344 patients by the Australasian Bone Marrow Transplant Recipient Registry (ABMTRR)

Status

Completed

Phases

Unknown

Study type

Observational

Source

ANZCTR

Registry ID

ACTRN12612000575831

Enrollment

350

Registered

2012-05-29

Start date

2009-05-16

Completion date

Unknown

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

Allogeneic haemopoietic stem cell transplantation (HSCT) is a potentially curative procedure for a wide range of haematological malignancies, but the benefit of the graft versus malignancy effect is often offset by increased toxicity of graft versus host disease (GVHD) and infection. Reduced intensity conditioning (RIC) regimens have become more commonly used over the last 10 years in HSCT in an attempt to provide the potential curative benefit of allografting to a wider patient population. Most published literature on RIC transplantation has concentrated on one disease and the relative benefit of a particular form of RIC conditioning in that disease setting. There have been few studies analyzing a commonly used regimen and assessing its benefit across several disease groups. Indeed, there is no consensus on the relative benefits of a certain RIC regimen even in myeloid or lymphoid malignancies as a general group of diseases. In this study, we retrospectively assess the relative benefits of FluMel RIC HSCT from 1998-2008, in a large cohort of patients with either lymphoid or myeloid malignancies.

Interventions

This was a multi-centre retrospective analysis of the Australia and New Zealand experience with reduced intensity conditioning using Fludarabine and Melphalan. Haematopoietic stem cell transplant recipients (HSCT) were selected from the Australian Bone Marrow Transplant Registry. All eligible fludarabine melphalan (i.e. reduced intensity) conditioned HSCTs performed in the participating centres between January 1998 to December 2008 were to be included for evaluation.

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

first allogeneic peripheral blood or bone marrow HSCT using Fludarabine Melphalan conditioning for lymphoid and myeloid malignancies between January 1998 and December 2008

Exclusion criteria

multiple myeloma acute lymphoblastic leukemia prior allogeneic HSCT

Outcome results